RxDoctor Payments DataLook up a doctor →

Jay Sulek, MD

Urology · Lebanon, TNNPI 1104187632

Payments from drug & device makers

$16,533in general payments, 2019–2025

Across 503 payments — averaging $32.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Boston Scientific$2K
  • Neotract Inc.$1K
  • Medtronic$1K
  • Sumitomo Pharma America, Inc.$828
  • Johnson & Johnson$708
  • plus $8K from 49 others

What the payments were for

  • Travel & lodging$2,78117%
  • Food & beverage$13,52582%
  • Education$2271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,533 in reported general payments places this provider in the 80th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$300,855
Medicare patients
585
Services billed
4,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix102$252,400
GemtesaVibegron131$130,800
MyrbetriqMirabegron124$105,914
Tamsulosin Hcl695$9,251
PremarinEstrogens, Conjugated18$7,773
Trospium Chloride ErTrospium Chloride34$5,823
Silodosin34$4,598
Testosterone Cypionate69$3,486
Finasteride219$3,243
Potassium Citrate ErPotassium Citrate41$3,040
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl11$2,681
Methenamine Hippurate17$1,167
Estradiol17$1,151
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$822
Oxybutynin Chloride ErOxybutynin Chloride25$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$828$383,200233 claims
Astellas Pharma US IncMyrbetriq$660$105,914124 claims
PfizerPremarin$680$7,77318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 276 urology providers in Tennessee.

Other urology in Lebanon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →